Biopharma & Life Sciences
AbCellera Biologics Executive Compensation (FY25)
ABCL · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 12, 2026
161 figures on this page: 156 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Carl Hansen was paid $6,293,085 in total compensation as Chief Executive Officer for fiscal 2025, and Hansen's total was 23.7% lower than the $8,245,492 reported for fiscal 2024. For fiscal 2025, the company reported a chief executive pay ratio of 52:1, against median employee compensation of $122,119. The say-on-pay proposal drew 92.9% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025. The disclosed peer group includes Absci, Adaptive Biotechnologies, Agios Pharmaceuticals, Allogene Therapeutics and Arcutis Biotherapeutics, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Carl Hansen: $8,245,492 → $6,293,085 (23.7% lower)
Say-on-pay support: 88.9% → 92.9% (4.0 points higher)
CEO pay ratio: 63:1 → 52:1 (17.5% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is AbCellera Biologics' chief executive and what were they paid?
Carl Hansen was paid $6,293,085 in total compensation as Chief Executive Officer for fiscal 2025. Hansen's total was 23.7% lower than the $8,245,492 reported for fiscal 2024.
What was AbCellera Biologics' say-on-pay result?
The say-on-pay proposal drew 92.9% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in AbCellera Biologics' peer group?
The disclosed peer group includes Absci, Adaptive Biotechnologies, Agios Pharmaceuticals, Allogene Therapeutics and Arcutis Biotherapeutics, among others.
What is AbCellera Biologics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 52:1, against median employee compensation of $122,119.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carl Hansen Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Neil Aubuchon Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | — not reconciled |
Andrew Booth Chief Financial Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Véronique Lecault Chief Operating Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Tryn Stimart Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carl Hansen Chief Executive Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Andrew Booth Chief Financial Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Véronique Lecault Chief Technology Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carl Hansen Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Andrew Booth Chief Financial Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Véronique Lecault Chief Technology Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carl Hansen Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Andrew Booth Chief Financial Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Véronique Lecault Chief Technology Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Booth | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Carl L.G. Hansen | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Tryn Stimart | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Véronique Lecault | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Véronique Lecault | Option | ◇ | — | ◇ | 12/1/2032 |
| Option | ◇ | — | ◇ | 1/14/2034 | |
| Option | ◇ | — | ◇ | 1/1/2035 | |
| Andrew Booth | Option | ◇ | — | ◇ | 1/14/2034 |
| Option | ◇ | — | ◇ | 12/1/2032 | |
| Option | ◇ | — | ◇ | 1/1/2035 | |
| Carl Hansen | Option | ◇ | — | ◇ | 1/14/2034 |
| Option | ◇ | — | ◇ | 1/1/2035 | |
| Option | ◇ | — | ◇ | 12/1/2032 | |
| Tryn Stimart | Option | ◇ | — | ◇ | 12/1/2032 |
| Option | ◇ | — | ◇ | 1/14/2034 | |
| Option | ◇ | — | ◇ | 1/1/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
John S. Montalbano | ◇ | — | ◇ | — | — | — | ◇ |
Andrew Lo | ◇ | — | ◇ | — | — | — | ◇ |
Carl L.G. Hansen, Michael Hayden, Véronique Lecault and Stephen R. Quake served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Absci ABSI
- Adaptive Biotechnologies ADPT
- Agios Pharmaceuticals AGIO
- Allogene Therapeutics ALLO
- Arcutis Biotherapeutics ARQT
- Entrada Therapeutics TRDA
- Ligand Pharmaceuticals LGND
- Nurix Therapeutics NRIX
- Prime Medicine PRME
- Recursion Pharmaceuticals RXRX
- Regenxbio RGNX
- Relay Therapeutics RLAY
- Sana Biotechnology SANA
- Spyre Therapeutics SYRE
- Structure Therapeutics GPCR
- Verve Therapeutics VERV
- Vir Biotechnology VIR
- Xencor XNCR
- Xenon Pharmaceuticals XENE
- Y-mAbs Therapeutics YMAB
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 12, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 13, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 15, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact AbCellera Biologics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where AbCellera Biologics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
161 figures on this page: 156 cited to the filing that reported them, 5 calculated from figures it prints.
156 cited to the filing
5 calculated from the filing
Documents cited
- 0001703057-26-000033Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001703057-26-000020DIRECTOR COMPENSATION · Non-Employee Director Compensation Table · Outstanding Equity Awards at Fiscal Year End
- 0001628280-25-031219Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-25-0207032024 Summary Compensation Table
- 0001628280-24-028097Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-24-0190192023 Summary Compensation Table
- 0001703057-23-000014Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-23-0216642022 Summary Compensation Table
- 0001564590-22-023707Say-on-Pay Proposal
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “AbCellera Biologics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ABCL (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about AbCellera Biologics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers AbCellera Biologics discloses
The companies named in ABCL's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}